※ 본 기사문(영문ver.)은 (주)도프의 이슈를 다룬 기사를 자체적으로 영문번역하였음을 밝힙니다.

 

기사 원문 : 도프, 대한말초신경수술학회서 ‘초임계 공법 신경 공정 소개’ (edaily.co.kr)

 

DOF announced on the 6th that it attended the ‘2023 Korean Society of Peripheral Nerve Surgery’ held at Dong-A University in Busan on the 2nd and presented research on allogeneic nerve graft materials.

 

At the '2023 Korean Society of Peripheral Nerve Surgery' held at Dong-A University in Busan on the 2nd, CEO Shin Yong-woo of DOP introduced the current status of allograft nerve transplantation and the special advantages of the company's core technology, the supercritical nerve process and allograft nerve graft material (product name: SC CONNECT). there is. (Photo = DOF)

 

The Korean Society of Peripheral Nerve Surgery was established to specialize in the field of surgery and research on peripheral nerve diseases among the academic activities of the Korean Society of Hand Surgery.

 

 In a joint session at this event, CEO Shin Yong-woo of DOP introduced the current status of allograft nerve transplantation and the special advantages of the company's core technology, the supercritical nerve process and allograft nerve graft material (product name: SC CONNECT).

 

He said, “We can provide a safe nerve graft material whose effectiveness has been proven through the supercritical decellularization process,” and “We can supply customized diameter and length considering user convenience.”

 

Meanwhile, DOF succeeded in decellularizing and commercializing allogeneic tissues such as skin and nerve conduits for the first time in the world using a supercritical method. It is currently being supplied to major general hospitals in Korea. The goal is to be listed in 2025.